Latest news with #GSK
Yahoo
an hour ago
- Business
- Yahoo
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth
British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance. Driven by exceptional growth in Specialty Medicines and Vaccines, GSK's second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding analyst estimates of $10.33 billion. Core earnings jumped 15% at constant currency to $1.24 per share (46.5 pence) outperforming the consensus forecast of $ company attributed this core earnings growth to the strong performance of its Specialty Medicines and Vaccines divisions, coupled with higher royalty income and a disciplined escalation of investment in key research and development (R&D) areas, particularly within Oncology and Vaccines. Vaccine sales jumped 5% (+9% at constant currency or cc) to 2.09 billion pounds, reflecting growth in Meningitis vaccines related to uptake following expanded recommendation and public funding of Bexsero in Europe, as well as growth in Shingrix driven by launch uptake in France and strong demand across several other European markets and Japan. Arexvy sales reached 66 million pounds, up 6% (+13% cc). Meningitis vaccine sales increased 17% (+22% cc) to 379 million, while established vaccine sales of 787 million increased 2% (+6% cc). Shingrix sales reached 853 million pounds, up 3% (+6% cc). In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk. Also in July, the FDA extended the review period for the Biologics License Application (BLA) for GSK's Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. View more earnings on GSK Specialty Medicines sales grew by double-digit percentages (+10% and 15% cc) in the quarter to 3.33 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology & Inflammation, and Oncology. General Medicines sales fell by 10% (-6% cc) to 2.57 billion pounds. GSK is progressing on 14 major pipeline opportunities, each with a potential value of over 2 billion pounds, set to launch between 2025 and 2031. Phase 3 study for tebipenem, a new antibiotic for complicated urinary tract infections, was stopped early because it worked so well. The company plans to file for approval by the end of the year. Phase 3 development for depemokimab, aimed at treating COPD, has begun with the launch of the ENDURA study program. Key trials expected to begin in the second half of 2025 include GSK'227, a B7H3-targeting antibody-drug conjugate for small cell lung cancer, GSK'981 (IDRx-42) for second-line treatment of gastrointestinal stromal tumors, Efimosfermin for MASH, and an ultra-long-acting injectable HIV treatment combining cabotegravir and rilpivirine, to be given every four months. Tariff Outlook and Guidance Addressing a broader macroeconomic concern, GSK acknowledged the U.S. Administration's initiation of an investigation under Section 232 of the Trade Expansion Act, which seeks to ascertain the potential effects of pharmaceutical product imports on national security. The company said it is well-positioned to respond to the potential financial impact of tariffs, with mitigation options identified. According to Reuters, GSK's CFO indicated an anticipation of some tariffs coming in the second half of the year, which are expected to lower the gross margin slightly. GSK raised its full-year 2025 guidance and says it includes tariffs enacted thus far and the European tariffs indicated this week. It now expects sales to increase toward the top of the 3%–5% range. Core operating profit and earnings are also expected to grow towards the top end of the 6% to 8% range. Specialty Medicine sales are expected to increase in the low teens versus prior guidance of a low double-digit percentage. Vaccine revenue is expected to decline by a low single-digit percent to broadly stable compared to the prior outlook of a decrease of low single-digit percent, and general medicine sales are expected to be broadly stable. Price Action: At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session. Read Next:Photo by HJBC via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? GSK (GSK): Free Stock Analysis Report This article GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New Straits Times
an hour ago
- Business
- New Straits Times
Owner offered to sell Kelantan FC for RM300,000 amid confusion
KUALA LUMPUR: Kelantan FC owner Norizam Tukiman revealed that he had offered to sell his team to Gerakan Selamatkan Kelantan (GSK), led by Nik Hafiz Naim Nik Hassan, for RM300,000. However, Norizam said that the offer, which included a "large discount," did not receive a response from GSK. "I gave them options for free and for sale, but GSK didn't accept, instead wanting to buy and 'control' TRW Kelantan FC completely. "Discussions started from RM3 million, and eventually, I agreed to sell the majority stake for RM300,000, but in the end, there was no answer from Nik Hafiz. "I also contacted Nik Hafiz regarding this payment, but then suddenly, there was silence," Norizam said in a post on his Facebook page. Norizam claimed that Nik Hafiz decided to establish Kelantan Red Warriors (KRW) after negotiations to purchase shares in Kelantan FC fell through. "Instead, Nik Hafiz directly met with the Kelantan Football Association (KAFA) and the Amateur Football League (AFL) and established KRW. "I see KRW wanting to become TRW, using the name Kelantan Red Warriors along with the logo that is officially owned by TRW. "Today, people are confused that there's another TRW from Kelantan Darul Naim. To me, this confusion wouldn't be an issue if the AFL and the FA of Malaysia drafted a specific law about names," said Norizam.
Yahoo
2 hours ago
- Business
- Yahoo
GSK reports improved outlook despite US drug tariffs
British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter. GSK, which makes medicines in the European Union as well as in Britain and the United States, said its guidance took into account "the European tariffs indicated this week". The EU-US trade deal reached at the weekend set a 15 percent tariff on most European Union goods imported into the United States, though it is thought that Washington could still take steps that would see medicines face a higher levy. Despite the backdrop, GSK chief executive Emma Walmsley said the group expected to be "towards the top end of" its financial guidance for 2025 and remained "confident" over the longer term. "GSK's strong momentum in 2025 continues with another quarter of excellent performance driven mainly by specialty medicines, our largest business, with double-digit sales growth in respiratory, immunology and inflammation, oncology and HIV," she added in a statement. Addressing an online press conference later Wednesday, Walmsley said GSK was "very well positioned" to increasingly supply the United States, its "number one priority market", from within the country. "Our overall planned investment in the US is in the tens of billions of dollars over the next five years," she added. The company said net profit jumped 23 percent to £1.44 billion ($1.92 billion) in the three months to the end of June compared with the second quarter in 2024. Group sales increased one percent to £8 billion, helped by a 36 percent increase in cancer treatments that offset falls for other drugs, including for influenza. Just over half of total revenue was earned in the US market during the second quarter. "The prognosis for GSK is looking positive," said Derren Nathan, head of equity research at Hargreaves Lansdown. "It hasn't let itself get too distracted by tariff uncertainty, with both second-quarter sales and earnings coming in ahead of market forecasts," he said. GSK shares advanced 1.0 percent in afternoon deals on the London stock exchange, bucking a downward trend on the benchmark FTSE 100 index. ode-bcp/ajb/js
France 24
2 hours ago
- Business
- France 24
GSK reports improved outlook despite US drug tariffs
GSK, which makes medicines in the European Union as well as in Britain and the United States, said its guidance took into account "the European tariffs indicated this week". The EU-US trade deal reached at the weekend set a 15 percent tariff on most European Union goods imported into the United States, though it is thought that Washington could still take steps that would see medicines face a higher levy. Despite the backdrop, GSK chief executive Emma Walmsley said the group expected to be "towards the top end of" its financial guidance for 2025 and remained "confident" over the longer term. "GSK's strong momentum in 2025 continues with another quarter of excellent performance driven mainly by specialty medicines, our largest business, with double-digit sales growth in respiratory, immunology and inflammation, oncology and HIV," she added in a statement. Addressing an online press conference later Wednesday, Walmsley said GSK was "very well positioned" to increasingly supply the United States, its "number one priority market", from within the country. "Our overall planned investment in the US is in the tens of billions of dollars over the next five years," she added. The company said net profit jumped 23 percent to £1.44 billion ($1.92 billion) in the three months to the end of June compared with the second quarter in 2024. Group sales increased one percent to £8 billion, helped by a 36 percent increase in cancer treatments that offset falls for other drugs, including for influenza. Just over half of total revenue was earned in the US market during the second quarter. "The prognosis for GSK is looking positive," said Derren Nathan, head of equity research at Hargreaves Lansdown. "It hasn't let itself get too distracted by tariff uncertainty, with both second-quarter sales and earnings coming in ahead of market forecasts," he said. GSK shares advanced 1.0 percent in afternoon deals on the London stock exchange, bucking a downward trend on the benchmark FTSE 100 index.
Reuters
3 hours ago
- Business
- Reuters
GSK expects sales, profit toward top of 2025 forecasts despite tariff, pipeline pressures
July 30 (Reuters) - GSK (GSK.L), opens new tab expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter expectations on Wednesday, in a boost to its efforts to fuel growth despite product development and tariff challenges. The British drugmaker is hoping to reach annual sales of over 40 billion pounds ($53.44 billion) by 2031, even as it faces potential pharmaceutical tariffs and drug pricing pressure in the world-leading U.S. market. "We're very well positioned and continue to be part of investments so that our portfolio in the U.S. is more and more supplied from the U.S.," CEO Emma Walmsley told journalists. She added that GSK was also in talks with President Donald Trump's administration, which is pushing drugmakers to cut prices, but offered few details. The U.S. pharmaceuticals market - worth around $635 billion - makes up slightly over half of GSK's sales and is central to its growth plans. GSK said it had accounted for levies already implemented by Washington and expected tariffs on Europe's exports under a new U.S.-EU trade deal, as well as possible duties resulting from a U.S. investigation into pharmaceutical imports. It expects 2025 revenue to increase between 3% and 5%, with core profit per share growth of 6% to 8% at constant currency rates. GSK is focusing on expanding its product pipeline as it faces rising competition and declining sales of top drugs and vaccines. It expects five new major approvals this year. While second-quarter turnover growth of 6% to nearly 8 billion pounds and earnings of 46.5 pence per share beat analyst estimates, investors are focused on GSK's pipeline as it awaits a final U.S. approval verdict on cancer drug Blenrep. Analysts say a rejection might force GSK to rethink its 2031 sales target as it is also bracing for patent expirations in its HIV portfolio. The company's HIV business, as well as specialty medicines, respiratory, and oncology divisions, recorded double-digit revenue growth in the quarter. But Barclays analysts cautioned HIV sales growth would be slower in the second half due to the timing of stock sales and availability. GSK expects currency headwinds to be a drag of 4% and 7% on 2025 sales and profit growth, respectively, on a reported basis. Its shares rose as much as 2% and were trading 1.5% higher at 1127 GMT. ($1 = 0.7486 pounds)
